interferon α-2b

Phase 2Small molecule

Merck & Co.

interferon α-2b is one of 90 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

MelanomaActive, not recruiting

Chronic HepatitisPhase 1/Phase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Libtayo

Regeneron

Phase 3

6 2

Carboplatin/paclitaxel

AstraZeneca

Phase 3

1 3

Fotemustine

Roche

Phase 3

2 4

Vusolimogene Oderparepvec

YYana Najjar

Phase 3

1 5

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 6

Allovectin-7

VVical

Phase 3

3 7

Intron a

Merck & Co.

Preclinical

4 8

Opdualag

Bristol-Myers Squibb

Preclinical

3 9

PEG-Intron

Merck & Co.

Preclinical

1 10

interferon α-2b

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

Recruiting·ZZhejiang Provincial People's Hospital·N/A·NCT06450145·15 enrolled

Acute Lymphoblastic Leukemia1 trial

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Completed·EEmory University·Phase 2·NCT00548847·15 enrolled

Chronic Hepatitis1 trial

A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

Completed·DDigna Biotech S.L.·Phase 1/2·NCT01121731·70 enrolled

Melanoma1 trial

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Completed· Merck & Co. logo

Merck & Co.··NCT00749684·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for interferon α-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — interferon α-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for interferon α-2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

interferon α-2b

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Acute Lymphoblastic Leukemia1 trial

Chronic Hepatitis1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News